Remarks/Arguments

Claims 1-21 are pending. Applicant is required to elect an invention from among Groups I – VIII. Claim 1 has been identified as linking the inventions of Groups I-IV. Claim 12 has been identified as linking the inventions of Groups V-VIII.

Group I Claims 2-5 and 11, drawn to a method of inhibiting a receptor tyrosine kinase (RTK) in a mammal comprising administering an extracellular RTK antagonist and an intracellular RTK antagonist to the mammal, wherein said RTK is EGFR.

Group II Claims 6, 7, and 11, drawn to a method of inhibiting a receptor tyrosine kinase (RTK) in a mammal comprising administering an extracellular RTK antagonist and an intracellular RTK antagonist to the mammal, wherein said RTK is a HER2 receptor.

Group III Claims 8, 9, and 11, drawn to a method of inhibiting a receptor tyrosine kinase (RTK) in a mammal comprising administering an extracellular RTK antagonist and an intracellular RTK antagonist to the mammal, wherein said RTK is VEGFR.

Group IV Claims 10-11, drawn to a method of inhibiting a receptor tyrosine kinase (RTK) in a mammal comprising administering an extracellular RTK antagonist and an intracellular RTK antagonist to the mammal, wherein said RTK is RAS or a RAS-Raf modulator.

Group V Claims 13-15 and 21, drawn to a pharmaceutical composition comprising an extracellular RTK antagonist and an intracellular RTK antagonist wherein said RTK is EGFR.

Group VI Claims 16, 17, and 21, drawn to a pharmaceutical composition comprising an extracellular RTK antagonist and an intracellular RTK antagonist wherein said RTK is a HER2 receptor.

Group VII Claims 18, 19, and 21, drawn to a pharmaceutical composition comprising an extracellular RTK antagonist and an intracellular RTK antagonist wherein said RTK is VEGFR.

Group VIII Claims 20-21, drawn to a pharmaceutical composition comprising an extracellular RTK antagonist and an intracellular RTK antagonist wherein said RTK is RAS protein or a RAS-Raf modulator.

In response, Applicant elects the claims of Group III in this application. Applicant acknowledges that linking claim 1 is subject to examination with Group III. Upon allowance of claim 1, the restriction requirement would be withdrawn with respect to Groups I, II, and IV.

Applicants are also required to elect a species of "intracellular RTK antagonist" from ZD1939 and OSI-774 and a species of "extracellular RTK antagonist" from ABX-EGF; EMD 72000; h-R3; and Y10.

Accordingly, applicants elect OSI-774 and ABX-EGF. Applicants respectfully request that, upon allowance of a generic claim, claims directed to non-elected species including all the limitations of the generic claim be considered in accordance with 37 C.F.R. § 1.141 and ultimately allowed. Of the claims of Groups I – IV, claims 3, 4, and 5 read on the elected species.

In view of the foregoing amendment, the application is now believed to be in condition for examination. Prompt consideration and allowance of the pending claims is respectfully requested.

Respectfully submitted,
KENYON & KENYON LLP

Date: September 4, 2007

By: _____
Lawrence P. Casson
Reg. No. 46,606

One Broadway
New York, NY 10004
Telephone: (212) 425-7200
Facsimile: (212) 425-5288